English
LAQ824 (NVP-LAQ824,Dacinostat) , CAS 404951-53-7
LAQ824 (NVP-LAQ824,Dacinostat) , CAS 404951-53-7
Artikelnummer
BPS27760-1
Verpackungseinheit
10 mg
Hersteller
BPS Bioscience
Verfügbarkeit:
wird geladen...
Preis wird geladen...
Products from BPS Bioscience require a minimum order value above 400€
Background: A recent study shows that LAQ824 induces chromatin changes at the level of the IL-10 gene promoter that lead to enhanced recruitment of the transcriptional repressors HDAC11 and PU.1 and inhibits IL-10 production in BALB/c murine macrophages.
Biological Activity: LAQ824 (NVP-LAQ824) is a novel HDAC inhibitor with IC50 of 32 nM. LAQ824 activates the p21 promoter with 50% of the maximal promoter activation (AC50) of 0.30 µM, which in turn, activates the p21 inhibitor gene. LAQ824 has been found to inhibit the growth of a variety of cancer cell lines, including H1299, a non-small cell lung carcinoma line, and HCT116, a colon cancer cell line with IC50 of 0.15 µM and 0.01 µM, respectively. LAQ824 also dose- and time-dependently inhibits the cell growth of breast cancer MDA435 cells, prostate cancer DU145 and PC3 cells and non-small cell lung cancer A549 cells, with IC50 value < 1 µM and induce apoptosis in human breast cancer SKBR-3, BT-474 and MB-468 cells.
CAS Number: 404951-53-7
Description: LAQ824 (also known as NVP-LAQ824 or Dacinostat), a derivative of 4-aminomethylcinnamic hydroxamic acid, is a novel and potent inhibitor of histone deacetylase (HDAC) that inhibits the activity of HDAC with IC50 value of 0.03 µM.
Solubility: Soluble in DMSO
Storage Stability: Store at or below -20°C. Solid form is stable at least 12 months from date of receipt, when stored as directed. Do not store aqueous solutions for more than one day.
Target: HDAC
Biosafety Level: Not applicable (BSL-1)
References: Catley L, et al. Blood. 2003 Oct 1;102(7):2615-22.
Background: A recent study shows that LAQ824 induces chromatin changes at the level of the IL-10 gene promoter that lead to enhanced recruitment of the transcriptional repressors HDAC11 and PU.1 and inhibits IL-10 production in BALB/c murine macrophages.
Biological Activity: LAQ824 (NVP-LAQ824) is a novel HDAC inhibitor with IC50 of 32 nM. LAQ824 activates the p21 promoter with 50% of the maximal promoter activation (AC50) of 0.30 µM, which in turn, activates the p21 inhibitor gene. LAQ824 has been found to inhibit the growth of a variety of cancer cell lines, including H1299, a non-small cell lung carcinoma line, and HCT116, a colon cancer cell line with IC50 of 0.15 µM and 0.01 µM, respectively. LAQ824 also dose- and time-dependently inhibits the cell growth of breast cancer MDA435 cells, prostate cancer DU145 and PC3 cells and non-small cell lung cancer A549 cells, with IC50 value < 1 µM and induce apoptosis in human breast cancer SKBR-3, BT-474 and MB-468 cells.
CAS Number: 404951-53-7
Description: LAQ824 (also known as NVP-LAQ824 or Dacinostat), a derivative of 4-aminomethylcinnamic hydroxamic acid, is a novel and potent inhibitor of histone deacetylase (HDAC) that inhibits the activity of HDAC with IC50 value of 0.03 µM.
Solubility: Soluble in DMSO
Storage Stability: Store at or below -20°C. Solid form is stable at least 12 months from date of receipt, when stored as directed. Do not store aqueous solutions for more than one day.
Target: HDAC
Biosafety Level: Not applicable (BSL-1)
References: Catley L, et al. Blood. 2003 Oct 1;102(7):2615-22.
| Artikelnummer | BPS27760-1 |
|---|---|
| Hersteller | BPS Bioscience |
| Hersteller Artikelnummer | 27760-1 |
| Green Labware | Nein |
| Verpackungseinheit | 10 mg |
| Mengeneinheit | STK |
| Produktinformation (PDF) |
|
| MSDS (PDF) |
|
Immer für Sie da
Gernot Ensinger, M.Sc.
Laurent Haze
